Interesting Article from MDLinx

MDLinx  Psychiatry 5 minutes to stay current Your Article Summary Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: A 6-year, multinational, single-arm, open-label study International Clinical Psychopharmacology, 06/02/14 McDonnell DP, et al. – The objective of this study was to assess the long–term safety and efficacy of olanzapine long–acting injection (LAI). Olanzapine LAI appeared effective as a long–term maintenance treatment, with a safety profile generally consistent with the known profile of oral olanzapine, except for injection–related events (including post–injection delirium/sedation syndrome). >> Click here to see the complete list Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: A randomized clinical trial JAMA, 05/21/14 Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs European Neuropsychopharmacology, 05/20/14 Cognitive training in mental disorders: Update and future directions American Journal of Psychiatry, 05/05/14